Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$1.09
+0.01 (+0.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $57.4M · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$806M
P/E
N/A
•EV/EBITDA
19.6x
↑ROE
-3.3%
↓Gross Margin
40.2%
↓Debt/Equity
0.84
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-17.8%
FCF CAGR
-6.1%
FCF margin
26.3%
FCF / Net income
-6.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $273.4M · net income $-11.8M · FCF $71.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $273.4M | $273.4M | $326.0M | $565.6M | $491.8M |
| Net Income | $-11.8M | $-11.8M | $-188.8M | $-36.3M | $-34.6M |
| EBITDA | $52.3M | $52.3M | $-128.6M | $18.9M | $15.6M |
| EPS | — | — | -0.26 | -0.05 | -0.05 |
| Gross Margin | 40.2% | 40.2% | 49.9% | 53.0% | 45.8% |
| Operating Margin | 5.3% | 5.3% | -17.8% | 5.0% | 7.9% |
| Net Margin | -4.3% | -4.3% | -57.9% | -6.4% | -7.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.84 | 0.84 | 1.04 | 0.61 | 0.37 |
| Current Ratio | 0.56 | 0.56 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $71.8M | $71.8M | $57.4M | $-108.7M | $86.6M |
| Returns | |||||
| ROE | -3.3% | -3.3% | -51.1% | -6.4% | -5.6% |
| Valuation | |||||
| EV/EBITDA | 19.57 | 19.57 | — | 71.55 | 74.52 |
| P/B | 2.24 | 2.24 | 1.60 | 1.86 | 1.72 |
| Growth & Yield | |||||
| Revenue Growth | -16.2% | -16.2% | -42.4% | 15.0% | — |
| EPS Growth | — | — | -410.0% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+179.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.26 → n/d
Residual
+179.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.